Veterinary Drug terms — page 3 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

7-Ethyl-2-methyl-4-undecanol 4-(hydrogen sulphate) sodium salt (1:1) Sodium tetradecyl sulfate; EINECS 205-380-3
7beta-Hydroxycholesterol (3beta,7beta)-Cholest-5-ene-3,7-diol; 7beta-Hydroxycholesterol; 566-27-8; (3beta,7beta)-Cholest-5-ene-3,7-diol; 5-cholestene-3beta,7beta-diol; 7-HYDROXYCHOLESTEROL; CHEBI:42989; UNII-N9616291J4; (7beta)-hydroxycholesterol; 7-beta-Hydroxy-Cholesterol; CHEMBL497834; cholest-5-ene-3beta,7beta-diol; N9616291J4; (3S,7R,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; 7-beta-OHC; 7-Hydroxycholesterol, (7beta)-; 7b-Hydroxycholesterol; 7bet.-Hydroxycholesterol; Cholest-5-ene-3,7-diol, (3beta,7beta)-; 7.beta.-Hydroxycholesterol; SCHEMBL532559; GTPL4352; 5-Cholestene-3bet.,7bet.-diol; ZINC5758832; BDBM50045545; LMST01010047; MFCD00058406; DB04706; (3S,7R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; (3.beta.,7.beta.)-7-Hydroxycholest-5-en-3-ol; 566H278; C-46202; Q27074031; (3beta,7alpha,14beta,17alpha)-cholest-5-ene-3,7-diol; (3S,7R,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; 7-Hydroxycholesterol, (7beta)-
8-Azaguanine 5-Amino-3,6-dihydro-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one; Azaguanine; B-28
AZATHIOPRINE azathioprine; 446-86-6; Imuran; Azothioprine; Azathioprin; Azamun; Azatioprin; Azanin; Imurel; Azathiopurine; Azasan; Ccucol; Imurek; Muran; Rorasul; Azamun [Czech]; NSC-39084; BW 57-322; BW-57-322; NCI-C03474; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; Imuran (TN); 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; NSC 39084; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; Methylnitroimidazolylmercaptopurine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; UNII-MRK240IY2L; CCRIS 62; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; C9H7N7O2S; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; Azathioprine (Azasan, Imuran); 1H-Purine, 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-; 1H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; Purine, 6-(1-methyl-4-nitro-5-imidazolylthio)-; HSDB 7084; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; EINECS 207-175-4; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; MRK240IY2L; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; BW 57322; AI3-50290; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-9H-purine; CHEBI:2948; B. W. 57-322; LMEKQMALGUDUQG-UHFFFAOYSA-N; NSC39084; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; Purine, 6-((1-methyl-4-nitroimidazol-5-yl)thio)-; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine; NCGC00015060-06; NCGC00015060-14; AzatiopriCytostatics; CAS-446-86-6; Immuran; DSSTox_CID_119; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; DSSTox_RID_75381; DSSTox_GSID_20119; 6-((1-methyl-4-nitro-1H-imidazol-5-yl)thio)-7H-purine; Azamune; azatiopr in; Azasan (TN); SR-01000075537; Azathioprine [USAN:INN:BAN:JAN]; Purine, 6-[(1-methyl-4-nitroimidazol-5-yl)thio]-; 6-(1-methyl-4-nitro-1H-imidazol-5-ylthio)-9H-purine; azanine; Azothioprin; Azoran; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; Prestwick_41; Azathiopurine,(S); MFCD00069203; [Methyl(nitroimidazolyl)mercaptopurine]; PubChem9256; Azathioprine [USAN:USP:INN:BAN:JAN]; Spectrum_000064; Azathioprine, >=98%; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 55774-33-9; Prestwick0_000094; Prestwick1_000094; Prestwick2_000094; Prestwick3_000094; Spectrum2_000068; Spectrum3_000308; Spectrum4_000243; Spectrum5_000848; Lopac-A-4638; ChemDiv1_002659; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; A 4638; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); SCHEMBL4278; CHEMBL1542; Lopac0_000027; Oprea1_375441; Oprea1_533384; Oprea1_633462; Azathioprine(Azasan, Imuran); BSPBio_000048; BSPBio_001876; CBDivE_013132; KBioGR_000646; KBioGR_002427; KBioSS_000464; KBioSS_002433; MLS001049307; DivK1c_000586; SPECTRUM1500133; SPBio_000255; SPBio_001987; BPBio1_000054; GTPL7120; DTXSID4020119; Azathioprine (JP17/USP/INN); HMS501N08; HMS594I19; KBio1_000586; KBio2_000464; KBio2_002427; KBio2_003032; KBio2_004995; KBio2_005600; KBio2_007563; KBio3_001376; KBio3_002906; KS-00000XLZ; cMAP_000046; NINDS_000586; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; HMS1568C10; HMS1920E17; HMS2091K19; HMS2095C10; HMS2802J03; HMS3259P03; HMS3260E15; HMS3655M04; HMS3712C10; Pharmakon1600-01500133; ACT02232; BCP09492; HY-B0256; ZINC4258316; Tox21_110074; Tox21_400024; Tox21_500027; BDBM50373919; BG0097; CCG-16168; CCG-39877; GP1145; LS-123; NSC755900; s1721; STK831906; AKOS005609209; AKOS028108935; Tox21_110074_1; AC-4230; API0001569; CCG-220094; CS-2241; DB00993; KS-1146; LP00027; MCULE-8637589610; NC00614; NSC-755900; SDCCGMLS-0065415.P001; SDCCGSBI-0050016.P005; IDI1_000586; NCGC00015060-01; NCGC00015060-02; NCGC00015060-03; NCGC00015060-04; NCGC00015060-05; NCGC00015060-07; NCGC00015060-08; NCGC00015060-09; NCGC00015060-10; NCGC00015060-11; NCGC00015060-12; NCGC00015060-13; NCGC00015060-15; NCGC00015060-16; NCGC00015060-18; NCGC00015060-19; NCGC00090836-01; NCGC00090836-02; NCGC00090836-03; NCGC00090836-04; NCGC00090836-05; NCGC00090836-06; NCGC00094593-01; NCGC00094593-02; NCGC00094593-03; NCGC00260712-01; AK-98682; CC-24218; CPD000427366; L996; SAM002589938; SC-04582; SMR000427366; 6-1'-Methyl,5'-imidazolyl mercaptopurine; SBI-0050016.P003; AB0014998; AB2000247; 6-(1-Methyl-4-nitromidazol-5-ylthio)purine; AB00443544; EU-0100027; FT-0083532; FT-0602904; ST24045004; SW198560-2; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purine; Azathioprine, meets USP testing specifications; 1767-EP0930075A1; 1767-EP2272822A1; 1767-EP2272825A2; 1767-EP2272827A1; 1767-EP2272832A1; 1767-EP2275420A1; 1767-EP2277865A1; 1767-EP2277876A1; 1767-EP2281815A1; 1767-EP2292227A2; 1767-EP2292614A1; 1767-EP2295409A1; 1767-EP2295412A1; 1767-EP2295413A1; 1767-EP2295426A1; 1767-EP2295427A1; 1767-EP2298743A1; 1767-EP2301933A1; 1767-EP2311827A1; 1767-EP2311837A1; 1767-EP2314590A1; 1767-EP2316834A1; 1767-EP2371811A2; C06837; D00238; Q18939; AB00443544-03; AB00443544-11; AB00443544_12; AB00443544_13; Azasan; Imuran; Azamun; BW-57-322; NSC-39084; 055A974; 446A866; AG-670/36150031; C-17433; SR-01000762955; 6-(1-Methyl-4-nitro-5-imidazolythio)-9H-pur-ine; SR-01000075537-1; SR-01000075537-4; SR-01000762955-2; BRD-K32821942-001-05-6; BRD-K32821942-001-10-6; BRD-K60324116-001-01-5; WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW; Z57063156; 6-(3-methyl-5-nitro-imidazol-4-yl)sulfanyl-9H-purine; 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-1H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-9H-purine; 9H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-; Azathioprine, European Pharmacopoeia (EP) Reference Standard; 6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-1H-purine #; Azathioprine, United States Pharmacopeia (USP) Reference Standard; Azathioprine, Pharmaceutical Secondary Standard; Certified Reference Material; Azathioprine; AI3-50290
Acamprosate 3-(Acetylamino)-1-propanesulfonic acid; Acamprosate; Acamprosato [INN-Spanish]
Acarbose O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1->4)-O-alpha-D-glucopyranosyl-(1->4)- D-glucose; Acarbose; Acarbosa [INN-Spanish]
Aceclofenac 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid carboxymethyl ester; Aceclofenac; Aceclofenac
Acetazolamide acetazolamide; 59-66-5; Diamox; N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide; Acetazolamid; Diacarb; Glaupax; Defiltran; Nephramide; Acetamox; Cidamex; Diluran; Edemox; Dehydratin; Diuramid; Diutazol; Duiramid; Eumicton; Natrionex; Nephramid; Phonurit; Diakarb; Donmox; Fonurit; Glupax; Vetamox; Didoc; SK-acetazolamide; Diuriwas; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide; Acetazoleamide; Acetozalamide; Diureticum-holzinger; Acetamidothiadiazolesulfonamide; Acetazolamida; Acetazolamidum; 4-Diamox; Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; Carbonic Anhydrase Inhibitor No. 6063; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; Acetazolamidum [INN-Latin]; Acetazolamida [INN-Spanish]; 2-Acetamido-5-sulfonamido-1,3,4-thiadiazole; Carbonic anhydrase inhibitor 6063; UNII-O3FX965V0I; N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide; NSC 145177; 1,3,4-Thiadiazole-2-sulfonamide, 5-acetamido-; C4H6N4O3S2; CCRIS 5811; HSDB 3002; 5-Acetamide-1,3,4-thiadiazole-2-sulfonamide; CHEMBL20; EINECS 200-440-5; MFCD00003105; Diamox (TN); N-(5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide; AI3-52458; MLS000028435; O3FX965V0I; CHEBI:27690; BZKPWHYZMXOIDC-UHFFFAOYSA-N; Acetamide, N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-; NSC-145177; CAS-59-66-5; NCGC00015074-10; Acetazolamine; Acetamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)-; Atenezol; Diuramide; Glaumox; SMR000058394; Diamox Sequels; DSSTox_CID_2544; 5-acetylamino-1,3,4-thiadiazole-2-sulfonamide; DSSTox_RID_76621; DSSTox_GSID_22544; N-(5-[Aminosulfonyl]-1,3,4-thiadiazol-2-yl)acetamide; N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide; Acetazolamide [INN:BAN:JAN]; Acetazolamide (AAZ); Acetazolamide Sodium, (Sterile); SR-01000000065; Prestwick_4; 1azm; 1yda; 1ydb; 1ydd; 1zsb; 2xtk; 3czv; 3ucj; Acetazolamide, 5; Acetazolamide [USP:INN:BAN:JAN]; Acerazolamide, AAZ; Acetazolamide, AAZ; Acetazolamide, AZA; Acetazolamide, AZM; ACMC-20gwkd; PubChem12858; Spectrum_000018; 1jd0; 2h4n; 2uy4; 3dc3; 3hs4; 3ml5; 4g0c; Opera_ID_288; AZA2; Prestwick0_000003; Prestwick1_000003; Prestwick2_000003; Prestwick3_000003; Spectrum2_000082; Spectrum3_000284; Spectrum4_000139; Spectrum5_000738; Lopac-A-6011; A 6011; Lopac0_000039; SCHEMBL23219; BSPBio_000005; BSPBio_001788; KBioGR_000558; KBioSS_000358; KSC270I0P; MLS001148438; BIDD:GT0643; DivK1c_000017; SPECTRUM1500102; N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-acetamide; SPBio_000004; SPBio_001926; BPBio1_000007; GTPL6792; (non-d)Acetazolamide-13C2-d3; Acetazolamide, >=99%, powder; DTXSID7022544; SCHEMBL11049053; BDBM10880; BZKPWHYZMXOIDC-UHFFFAOYSA-; CTK1H0407; HMS500A19; KBio1_000017; KBio2_000358; KBio2_002926; KBio2_005494; KBio3_001288; KS-00000UPN; Acetazolamide (JP17/USP/INN); N-[5-(Aminosulfonyl)-1,3,4-thiadiozol-2-yl]-Acetamide; Acetazolamide, analytical standard; NINDS_000017; HMS1568A07; HMS1920A05; HMS2091G05; HMS2095A07; HMS2232G23; HMS3259I13; HMS3260G19; HMS3370P01; HMS3712A07; HMS3744A21; Pharmakon1600-01500102; WLN: T5NN DSJ CSZW EMV1; ALBB-023617; BCP29616; EBD55026; HY-B0782; ZINC3813042; Tox21_110078; Tox21_201559; Tox21_302773; Tox21_500039; CCG-38900; NSC145177; NSC755854; s4506; SBB056640; AKOS000715163; Tox21_110078_1; CS-3568; DB00819; LP00039; MCULE-4029778803; NC00491; NSC-755854; SDCCGSBI-0050028.P005; Acetazolamide Related Compound (5-acetamido-1,3,4-thiadiazole-2-sulfonic acid); IDI1_000017; NCGC00015074-01; NCGC00015074-02; NCGC00015074-03; NCGC00015074-04; NCGC00015074-05; NCGC00015074-06; NCGC00015074-07; NCGC00015074-08; NCGC00015074-09; NCGC00015074-11; NCGC00015074-12; NCGC00015074-14; NCGC00015074-15; NCGC00023455-03; NCGC00023455-04; NCGC00023455-05; NCGC00023455-06; NCGC00023455-07; NCGC00256374-01; NCGC00259108-01; NCGC00260724-01; AC-12779; AK324920; AS-13169; CPD000058394; H501; LS-10227; SAM002554883; SC-20738; SBI-0050028.P004; 2-Acetamido-5-sulfonamido-1,4-thiadiazole; 5-Acetamide-1,4-thiadiazole-2-sulfonamide; DB-053437; 5-Acetamido-1,3,4-thiadiazol-2-sulfonamide; AB00051906; EU-0100039; FT-0621733; R1055; ST45022057; 1,4-Thiadiazole-2-sulfonamide, 5-acetamido-; C06805; D00218; J10059; 20506-EP2269989A1; 20506-EP2275420A1; 20506-EP2280008A2; 20506-EP2295406A1; 20506-EP2298772A1; 20506-EP2308562A2; 20506-EP2308839A1; 20506-EP2314585A1; AB00051906_15; 003A105; A832415; N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)ethanamide; Q413690; L 579486; Q-200579; Q-200580; SR-01000000065-2; SR-01000000065-4; SR-01000000065-6; BRD-K43457670-001-22-9; BRD-K43457670-001-26-0; Z277559108; Acetazolamide, European Pharmacopoeia (EP) Reference Standard; Acetazolamide, United States Pharmacopeia (USP) Reference Standard; N - (5 - Sulfamoyl - 1,3, 4 - thiadiazol - 2 - yl) acetamide; Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Acetazolamide, Pharmaceutical Secondary Standard; Certified Reference Material; 2-Acetamido-5-sulfamoyl-1,3,4-thiadiazole; 2-Acetylamino-1,3,4-thiadiazole-5-sulfonamide; 5-Acetamido-1,3,4-thiadiazole-2-sulfonamide; InChI=1/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9); 6063
Acetoacetic acid 3-Oxobutanoic acid; Acetoacetic acid; Acetoacetate
Acetohexamide 4-Acetyl-N-[[cyclohexylamino]carbonyl]benzenesulfonamide; Acetohexamide; U 14812
Acetohydroxamic acid N-Hydroxyacetamide; acetohydroxamic acid; N-Hydroxyacetamide; 546-88-3; Methylhydroxamic acid; Acetic acid, oxime; Lithostat; Acetylhydroxamic acid; Acetohydroximic acid; N-Acetylhydroxylamine; Acetamide, N-hydroxy-; Acethydroxamsaeure; cetohyroxamic acid; Acetohydroxamate; Acethydroxamsaure; N-Acetyl hydroxyacetamide; Acethydroxamic acid; AHA; Hydroxylamine, N-acetyl-; Acido acetohidroxamico; Acide acetohydroxamique; Acidum acetohydroxamicum; Acethydroxamsaeure [German]; Acide acetohydroxamique [French]; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum [Latin]; UNII-4RZ82L2GY5; n-hydroxy-acetamide; NSC 176136; CCRIS 1730; HSDB 3585; EINECS 208-913-8; MFCD00009994; AI3-62232; 4RZ82L2GY5; CHEBI:27777; RRUDCFGSUDOHDG-UHFFFAOYSA-N; NSC-176136; NCGC00094576-01; DSSTox_CID_2546; WLN: QMV1; Acetyl hydroxyamino; DSSTox_RID_76622; DSSTox_GSID_22546; Acetohydroxamic acid, 98+%; ACETOHYDROXAMICACID; Lithostat (TN); CAS-546-88-3; Acetohydroxamic acid [USAN:INN]; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; acetohydroxamsaure; Acetohydroxamic acid (USP/INN); acetic acid oxime; Acetic acid|oxime; N-Oxylatoacetamide; acethydroximic acid; Acetohyroxamic acid; Acetyl hydroxyamine; Prestwick_38; N-oxidanylethanamide; acetohydroxarnic acid; zlchem 200; Acetohydroxamic acid [USAN:USP:INN]; methyl hydroximic acid; Spectrum_000020; ACMC-1AWJW; Spectrum2_000109; Spectrum3_000285; Spectrum4_000138; Spectrum5_000812; CH3C(O)NHOH; CHEMBL734; Acetohydroxamic acid, 98%; BSPBio_001790; KBioGR_000556; KBioSS_000360; KSC269I4N; MLS001076662; DivK1c_000821; SPECTRUM1500103; SPBio_000098; Acetamide, N-hydroxy- (9CI); DTXSID7022546; CHEBI:49029; CTK1G9446; CTK8A6224; HMS502J03; KBio1_000821; KBio2_000360; KBio2_002928; KBio2_005496; KBio3_001290; KS-00000UQU; NSC5073; ZLC0003; NINDS_000821; ACETOHYDROXAMIC ACID (AHA); HMS1920A07; HMS2091G07; HMS2231M17; Pharmakon1600-01500103; ACT05768; HY-B1235; NSC-5073; STR08084; ZINC4658603; Tox21_111301; ANW-32160; BDBM50099857; CA0112; CCG-38927; NSC176136; NSC755855; s4602; AKOS000172340; Tox21_111301_1; AB01014; CS-4881; DB00551; EBD2201963; MCULE-2682231025; NSC-755855; RTR-019336; IDI1_000821; NCGC00094576-02; NCGC00094576-03; NCGC00094576-05; AK-43984; BP-13320; BR-43984; LS-13067; SC-18498; SMR000499570; SBI-0051270.P003; AB0010594; DB-052632; TR-019336; A0051; AM20100343; FT-0621796; ST24033130; EN300-36948; 46A883; C06808; D00220; M-3701; AB00051907_07; A830321; Q481822; SR-01000763642; SR-01000763642-2; W-105609; Acetohydroxamic acid, United States Pharmacopeia (USP) Reference Standard; Acetohydroxamic acid; Acetamide, N-hydroxy-
Acetone cyanohydrin 4-03-00-00785 (Beilstein Handbook Reference)
Acetopyrrothine Thiolutin; Thiolutin; 87-11-6; Acetopyrrothin; Acetopyrrothine; NSC 3927; UNII-02C005Q20B; NSC3927; BRN 0209485; N-(4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl)acetamide; C8H8N2O2S2; 02C005Q20B; 3-Acetamido-5-methylpyrrolin-4-one(4,3-d)-1,2-dithiole; 6-Acetamido-4-methyl-1,2-dithiolo(4,3-b)pyrrol-5(4H)-one; 6-(Acetylamino)-4-methyl-1,2-dithiolo(4,3-b)pyrrol-5(4H)-one; 1,2-DITHIOLO(4.3-b)PYRROL-5(4H)-ONE, 6-ACETAMIDO-4-METHYL-; N-{4-methyl-5-oxo-4H,5H-[1,2]dithiolo[4,3-b]pyrrol-6-yl}acetamide; N-(4,5-Dihydro-4-methyl-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)acetamide; W-203989; Farcinicin; Farcinicine; Propiopyvothine; N-Acetylpyrrothine; 1, 6-acetamido-4-methyl-; CHEMBL507026; SCHEMBL1718756; DTXSID0040624; CTK8G3435; BIT1001; BCP17046; HY-N6712; NSC-3927; MFCD07370147; AKOS024456672; WLN: T55 BNV FSSJ B1 DMV1; FCH1326391; NCGC00162456-01; AS-72926; LS-63347; NCI60_003708; Farcinicin; Propiopyvothine; Acetopyrrothine; CS-0029085; FT-0675180; 6-Acetamido-4-methyl-1,3-b]pyrrol-5[4H]-one; N-(4,2-dithiolo[4,3-b]pyrrol-6-yl)acetamide; 3-Acetamido-5-methylpyrrolin-4-one[4,2-dithiole; Q7784674; 6-(Acetylamino)-4-methyl-1,3-b]pyrrol-5[4H]-one; N-(4-methyl-5-oxo-dithiolo[4,3-b]pyrrol-6-yl)acetamide; N-(4,5-Dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-B]Pyrrol-6-yl); Acetamide,5-dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl)-; N-(4-methyl-5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide; N-(4-methyl-5-oxo-4,5-dihydro[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide; Acetamide, N-(4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)-; Acetamide, N-(4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)- (8CI); Acetamide, N-(4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)- (8CI)(9CI); Acetamide,N-(4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl)-; N-(4-methyl-3-oxo-7,8-dithia-4-azabicyclo[3.3.0]octa-1,5-dien-2-yl)acetamide; Acetopyrrothine; 4-27-00-06758 (Beilstein Handbook Reference)
Acetovanillone 1-(4-Hydroxy-3-methoxyphenyl)ethanone; Acetovanillone; apocynin; 498-02-2; 4'-Hydroxy-3'-methoxyacetophenone; 1-(4-Hydroxy-3-methoxyphenyl)ethanone; Acetoguaiacone; Acetoguaiacon; Apocynine; 4-Acetyl-2-methoxyphenol; Acetovanilone; Acetovanyllon; Ethanone, 1-(4-hydroxy-3-methoxyphenyl)-; 3-Methoxy-4-hydroxyacetophenone; 4-HYDROXY-3-METHOXYACETOPHENONE; Acetovanillon; 1-(4-hydroxy-3-methoxyphenyl)ethan-1-one; 4-Hydroxy-3-methoxyphenyl methyl ketone; Acetophenone, 4'-hydroxy-3'-methoxy-; NSC 209524; UNII-B6J7B9UDTR; EINECS 207-854-5; BRN 0637373; 3-Metoksy-4-hydroksyacetofenon; CCRIS 7285; 2-methoxy-4-acetylphenol; B6J7B9UDTR; 3-Metoksy-4-hydroksyacetofenon [Polish]; AI3-15892; CHEBI:2781; DFYRUELUNQRZTB-UHFFFAOYSA-N; NSC-209524; Acetovanillone, 98%; 1-(4-hydroxy-3-methoxy-phenyl)-ethanone; WLN: 1VR DQ CO1; 1-acetyl-4-hydroxy-3-methoxybenzene; 4-Acetylguaiacol; PubChem3315; 1-(4-hydroxy-3-methoxy-phenyl)ethanone; Acetovanillone; Apocynin; ACMC-1AHLR; apocynin (acetovanillone); bmse000584; bmse010031; AURORA KA-3667; Phenol, 4-acetyl-2-methoxy; 4-08-00-01814 (Beilstein Handbook Reference); KSC236I5L; MLS001304972; SCHEMBL109514; 4-hydroxy3-methoxyacetophenone; 4hydroxy-3-methoxyacetophenone; Acetovanillone, >=98%, FG; CHEMBL346919; DTXSID7060097; CTK1D6455; KS-00000WMF; TIMTEC-BB SBB008060; 4-hydroxy -3-methoxyacetophenone; NSC2146; Acetovanillone, analytical standard; HMS3651H03; ZINC162515; 3'-Methoxy-4'-hydroxyacetophenone; HY-N0088; NSC-2146; STR03975; AKOS BBS-00003229; ANW-30844; BBL009710; MFCD00008747; NSC209524; s2425; SBB008060; STL141075; ZINC00162515; AKOS000120562; 4-Hydroxy-3-methoxyphenyl methyl keton; AS03910; CM10957; CS-5647; DB12618; FS-3673; MCULE-4549346345; RTR-033392; 1-(4-hydroxy-3-methoxyphenyl)-ethanone; NCGC00247065-01; 4'-Hydroxy-3'-methoxyacetophenone, 98%; 4CN-0663; AC-29981; AK-42915; L911; LS-13569; SC-04834; SMR000752909; 1-(4-Hydroxy-3-methoxyphenyl)-1-ethanone; AB1003774; TR-033392; AM20090774; FT-0618638; ST24030066; ST50213415; SW219526-1; A11989; C11380; M-6166; 21432-EP2311824A1; 21432-EP2314295A1; AA-504/20839006; Q414754; Q-200477; ACETOPHENONE,4-HYDROXY,3-METHOXY ACETOVANILLON; F2191-0004; InChI=1/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H; I75; Acetovanillone; 4-08-00-01814 (Beilstein Handbook Reference)
Acetylcholine 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Acetylcholine; Choline acetate; O-Acetylcholine; 51-84-3; Acetyl choline ion; Acetylcholinum; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Ach; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; 2-acetyloxyethyl-trimethylazanium; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); [3H]acetylcholine; NCGC00018123-05; C7H16NO2; 2rin; 3rqw; Acetylcholine cation; (14C)Acetylcholine; (14C)-Acetylcholine; Spectrum_000022; 2ha4; 2xz5; Spectrum2_001258; Spectrum3_000286; Spectrum4_000136; Spectrum5_000762; Epitope ID:176773; cid_6060; SCHEMBL3216; BSPBio_001792; GTPL294; KBioGR_000552; KBioSS_000382; 4-04-00-01446 (Beilstein Handbook Reference); DivK1c_000686; SPBio_001196; Acetylcholinium: acetyl-Choline; GTPL8593; DTXSID8075334; BDBM10759; CTK4B9009; KBio1_000686; KBio2_000382; KBio2_002950; KBio2_005518; KBio3_001292; NINDS_000686; OIPILFWXSMYKGL-UHFFFAOYSA-N; HMS2089A14; ZINC3079336; DB03128; MCULE-7765616505; 2-acetyloxy-N,N,N-trimethylethanaminium; IDI1_000686; 2-acetoxyethyl(trimethyl)ammonium; bromide; NCGC00018123-01; NCGC00018123-02; NCGC00018123-03; NCGC00018123-04; NCGC00021161-03; NCGC00021161-04; NCGC00163215-01; LS-53168; SBI-0051271.P003; 2-acetoxyethyl(trimethyl)ammonium; perchlorate; FT-0689161; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl; 4774-EP2269989A1; 4774-EP2272537A2; 4774-EP2275420A1; 4774-EP2280006A1; 4774-EP2280010A2; 4774-EP2281813A1; 4774-EP2281824A1; 4774-EP2284171A1; 4774-EP2287163A1; 4774-EP2295437A1; 4774-EP2298734A2; 4774-EP2298758A1; 4774-EP2298759A1; 4774-EP2298772A1; 4774-EP2298775A1; 4774-EP2305644A1; 4774-EP2305664A1; 4774-EP2305675A1; 4774-EP2305678A1; 4774-EP2308839A1; 4774-EP2308873A1; 4774-EP2308875A1; 4774-EP2308876A1; 4774-EP2311823A1; 4774-EP2311828A1; 4774-EP2311831A1; 4774-EP2314571A2; 4774-EP2316836A1; C01996; 21686-EP2272972A1; 21686-EP2272973A1; 21686-EP2277872A1; 21686-EP2314571A2; 21686-EP2371803A1; 21686-EP2377843A1; AB00053790-25; AB00053790_26; AB00053790_27; L000783; Q180623; 2-(Acetyloxy)-N,N,N-trimethylethanaminium labeled with carbon-14; InChI=1/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, labeled with carbon-14 (9CI); 14047-05-3; Acetylcholine; 4-04-00-01446 (Beilstein Handbook Reference)
Acetylcysteine N-Acetyl-L-cysteine; N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; L-Acetylcysteine; Broncholysin; Fluimucil; Mucomyst; N-Acetyl-cysteine; Fluprowit; Parvolex; Acetein; Airbron; Fabrol; Fluimucetin; Flumucetin; Mucosolvin; Mucosil; Brunac; Fluimicil Infantil; AcetilcisteiAcetylcysteinum; Lysomucil; Mucofilin; Respaire; Exomuc; Inspir; Ac-Cys-OH; Mucolyticum Lappe; Mucolytikum Lappe; N-Acetyl cysteine; Mucolyticum; LNAC; N-Acetyl-3-mercaptoalanine; N-Acetyl-L-(+)-cysteine; Neo-fluimucil; NAC-TB; (R)-2-Acetamido-3-mercaptopropanoic acid; Mucolyticum-Lappe; Acetyl-L-cysteine; component of Naxid; Mercapturic acid, (R)-; Cysteine, N-acetyl-, L-; cysteine, N-acetyl-; L-Cysteine, N-acetyl-; (R)-mercapturic acid; NAC; Fluatox; Mucolator; Mucret; Tixair; N-acetylcystein; UNII-WYQ7N0BPYC; MUCOSIL-10; MUCOSIL-20; (2R)-2-acetamido-3-sulfanylpropanoic acid; (2R)-2-Acetamido-3-sulfanyl-propanoic acid; L-alpha-Acetamido-beta-mercaptopropionic acid; Acetylcysteinum [INN-Latin]; Acetilcisteina [INN-Spanish]; NSC 111180; CCRIS 3764; HSDB 3003; WYQ7N0BPYC; EINECS 210-498-3; MFCD00004880; MLS000028419; CHEBI:28939; PWKSKIMOESPYIA-BYPYZUCNSA-N; NSC-111180; NCGC00022304-05; SMR000058377; DSSTox_CID_21; (R)-2-acetylamino-3-mercaptopropanoic acid; (2R)-2-acetylamino-3-sulfanylpropanoic acid; (2R)-2-(acetylamino)-3-sulfanylpropanoic acid; DSSTox_RID_75324; DSSTox_GSID_20021; N-Acetyl-L-cysteine, 98%; Syntemucol; Cetylev; acetyl cysteine; Flumil; Ilube; Muco sanigen; CAS-616-91-1; SR-01000075439; Mucocedyl; AcCys; NSC111180; Acetylcysteine [USAN:INN:BAN]; N-acetyl-l-cys; 2-Acetylamino-3-mercapto-propionic acid; Sodium 2-acetamido-3-mercaptopropionate; SC2; (S)-2-Acetamido-3-mercaptopropanoic acid; N-acetyl-L-cystein; Naxid (Salt/Mix); N-Acety-L-Cysteine; Acetyl Cysteine,(S); PubChem12963; Acetylcysteine [USAN:USP:INN:BAN:JAN]; N-acetyl-(R)-cysteine; Opera_ID_452; MUCOMYST (TN); Spectrum2_000086; Spectrum3_000287; Spectrum4_000137; Spectrum5_000764; N-alpha-Acetyl-L-cysteine; CHEMBL600; NAC & TNF; SCHEMBL5292; Lopac0_000081; BSPBio_001794; KBioGR_000554; KSC352Q8P; MLS001076125; MLS006011563; SPBio_000012; DTXSID5020021; CTK2F2887; KBio3_001294; Acetylcysteine (JP17/USP/INN); HMS2234J22; HMS3260A04; HMS3655G11; HMS3715D03; HY-B0215; ZINC3589203; 2-Acetylamino-3-mercapto-propionate; Tox21_110877; Tox21_201078; Tox21_500081; acetylcysteine (n-acetyl-l-cysteine); ANW-33915; BDBM50420190; s1623; AKOS015841009; Tox21_110877_1; CCG-204176; CS-2160; DB06151; GS-3121; LP00081; LS-2165; RK-0202; RTC-066653; SDCCGSBI-0050069.P002; KS-0000026W; NCGC00015086-04; NCGC00022304-03; NCGC00022304-04; NCGC00022304-06; NCGC00022304-07; NCGC00022304-08; NCGC00258631-01; NCGC00260766-01; AC-16071; AC-24117; BP-12854; BR-46577; I630; SC-09436; AB0013800; AB1002786; DB-038288; ST2408139; TC-066653; A0905; AM20100502; EU-0100081; FT-0629832; ST50824849; SW199597-2; (2R)-2-acetylamino-3-mercapto-propionic acid; EN300-72028; (2R)-2-(acetylamino)-3-mercaptopropanoic acid; 16A911; A 7250; A-1100; C06809; D00221; L-Cysteine, N-acetyl- & Tumor necrosis factor; N-Acetyl-L-cysteine, BioXtra, >=99% (TLC); 66233-EP2298305A1; 66233-EP2308851A1; AB00382974-12; AB00382974_13; L-.alpha.-Acetamido-.beta.-mercaptopropionic acid; Q375613; ANTIOXIDANT MODEL (TRAMP) -N-ACETYLCYSTEINE; J-507685; N-Acetyl-L-cysteine & Tumor necrosis factor (TNF); SR-01000075439-1; SR-01000075439-3; SR-01000075439-5; BRD-K59058747-001-20-9; N-Acetyl-L-cysteine, cell culture tested, BioReagent; N-Acetyl-L-cysteine, Vetec(TM) reagent grade, 98%; F1905-7178; CABC898A-E48B-4E13-9F72-98D0609A1854; N-Acetyl-L-cysteine, SAJ special grade, 98.0-102.0%; N-Acetyl-L-cysteine, Sigma Grade, >=99% (TLC), powder; UNII-2SPH1IMO2V component PWKSKIMOESPYIA-BYPYZUCNSA-N; Acetylcysteine, British Pharmacopoeia (BP) Reference Standard; Acetylcysteine, European Pharmacopoeia (EP) Reference Standard; Acetylcysteine, United States Pharmacopeia (USP) Reference Standard; LNAC; NAC,L-alpha-Acetamido-beta-mercaptopropionic acid; Mercapturic acid; N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material; N-Acetyl-L-cysteine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; Acetylcysteine; 5052
Acetylenedicarboxamide Cellocidin; Cellocidin; ACETYLENEDICARBOXAMIDE; 2-Butynediamide; Lenamycin; but-2-ynediamide; 543-21-5; Aquamycin; Renamycin; Acetylene dicarboxamide; Acetylenedicarboxylic acid diamide; Acetylendicarbonsaeureamid; UNII-1K327HA41T; Acetylendicarbonsaeureamid [German]; NSC65381; NSC 38643; NSC 65381; BRN 1756134; CHEBI:51763; 1K327HA41T; WLN: ZV1UU1VZ; Acetylendicarboxamid; NCIMech_000799; But-2-ynedioic acid diamide; SCHEMBL1003846; CHEMBL1978380; DTXSID1060261; CTK1G9972; JBTGHKUTYAMZEZ-UHFFFAOYSA-N; NSC38643; ZINC1670806; CCG-35858; NSC-38643; NSC-65381; AKOS004907748; MCULE-4585775503; VZ31209; LS-13956; NCI60_003686; NCI60_018708; DB-007232; TC-030502; FT-0080441; FT-0602756; A830097; Q5058318; 102489-37-2; 4-02-00-02295 (Beilstein Handbook Reference)
Acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride;trihydrochloride Acriflavine, hydrochloride; Acriflavine dihydrochloride
Acrivastine (2E)-3-[6-[(1E)-1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]-2-pyridinyl]-2-propenoic acid; Acrivastine; Acrivastina [Spanish]
Acrylic acid 2-Propenoic acid; Acrylic acid; 4-02-00-01455 (Beilstein Handbook Reference)
Acyline N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-(acetylamino)-L-phenylalanyl-4-(acetylamino)-D-henylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide; Acyline; UNII-S3439D3B35
Adamantane ADAMANTANE; 281-23-2; Tricyclo[3.3.1.13,7]decane; Adamantan; Tricyclo[3.3.1.1(3,7)]decane; tricyclo[3.3.1.1~3,7~]decane; tricyclo[3.3.1.1]decane; UNII-PJY633525U; EINECS 206-001-4; NSC 527913; CHEBI:40519; Tricyclo(3.3.1.13,7)decane; ORILYTVJVMAKLC-UHFFFAOYSA-N; PJY633525U; MFCD00074719; Adamantane, 99+%; Adamantine; Adamantane (8CI); Adamantane; >99%; Adamantane, >=99%; ACMC-1CCIJ; EC 206-001-4; KSC203I8H; CHEMBL1230831; DTXSID5022017; CTK1A3483; ZINC1271109; ANW-26338; NSC527913; SBB056628; Tricyclo[3.3.1.1<3,7>]decane; AKOS000119960; AKOS004908007; DB03627; DS-4960; NSC-527913; RTR-012480; TRA0035650; Tricyclo(3,3,1,1,<3,7>)-decane; AK117357; AS-12242; SC-47025; DB-004015; LS-157064; TR-012480; A0696; FT-0083759; FT-0621893; ST24030068; ST50975605; A819332; Q351461; W-107075; F0001-0891; InChI=1/C10H16/c1-7-2-9-4-8(1)5-10(3-7)6-9/h7-10H,1-6H; EINECS 206-001-4
Adamantanone 2-Adamantanone; 2-Adamantanone; 700-58-3; Adamantan-2-one; Adamantanone; 2-Adamantone; 2-Oxoadamantane; Tricyclo[3.3.1.13,7]decanone; UNII-UI7W503L08; EINECS 211-847-2; MFCD00074737; NSC 126345; BRN 1210235; Tricyclo(3.3.1.1(sup 3,7))decanone; AI3-34003; CHEBI:40611; IYKFYARMMIESOX-UHFFFAOYSA-N; UI7W503L08; Tricyclo(3.3.1.13,7)decan-2-one; Tricyclo[3.3.1.13,7]decan-2-one; tricyclo[3.3.1.1~3,7~]decan-2-one; 2-Adamantanone, 98%; Tricyclo(3.3.1.13,7)decanone; Tricyclo[3.3.1.1(sup 3,7)]decanone; Tricyclo(3,3,1,13,7)decanone; 2-adamantanon; 2-admantanone; 2 -adamantanon; PubChem8730; ACMC-209ock; SCHEMBL71132; KSC378C7B; SCHEMBL4721541; CHEMBL2041316; DTXSID9022108; SCHEMBL10285140; SCHEMBL14094609; SCHEMBL14791313; CTK2H8170; KS-00000MRK; ACT02933; STR01057; Tricyclo[3.3.1.13,7]decaneone; ZINC3882578; ANW-35826; BBL007921; c0604; NSC126345; SBB015156; STK325358; Tricyclo[3.3.1.1(3,7)]decanone; AKOS001086414; AKOS005256545; AC-8482; CS-W019662; DB02125; EBD2197815; FS-4094; LS40248; NSC-126345; PS-3002; RTC-030650; 2-Adamantanone, ReagentPlus(R), 99%; tricyclo[3.3.1.13,7 ]decan-2-one; AC-16093; AK-45606; BR-45606; LS-15046; SC-06390; SY005737; tricyclo[3.3.1.1(3,7)]decan-2-one; Tricyclo(3.3.1.13,7)decanone (9CI); AB0068883; DB-005158; ST2412622; TC-030650; A0719; FT-0080581; FT-0600862; ST50182082; AZ0001-0406; M-3196; 2-Adamantanone, Vetec(TM) reagent grade, 98%; 700A583; A836754; Q-200226; Q27093191; F0001-1816; (1r,3r,5R,7R)-tricyclo[3.3.1.1~3,7~]decan-2-one; Adamantanone; Adamantanone
Adenine 9H-Purin-6-amine; adenine; 73-24-5; 6-Aminopurine; 1H-Purin-6-amine; 9H-Purin-6-amine; 7H-Purin-6-amine; Vitamin B4; Adenin; Adeninimine; Leuco-4; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 1,6-Dihydro-6-iminopurine; 3,6-Dihydro-6-iminopurine; Purine, 6-amino-; USAF CB-18; 1H-Purine, 6-amino; ADE; Adenine [JAN]; 9H-Purine, 1,6-dihydro-6-imino-; 1H-Purine-6-amine; CCRIS 2556; AI3-50679; NSC 14666; UNII-JAC85A2161; 9H-Purine-6-amine; 9H-purin-6-ylamine; CHEBI:16708; 1H-Purine, 6-amino-; EINECS 200-796-1; MFCD00041790; 1H-purin-6(9H)-imine; 3H-Purin-6(7H)-imine; CHEMBL226345; purine-6-ylamine; GFFGJBXGBJISGV-UHFFFAOYSA-N; JAC85A2161; NSC-14666; 134434-48-3; 66224-66-6; Adenine, 99%; NCGC00094856-01; Pedatisectine B; DSSTox_CID_2557; DSSTox_RID_76627; DSSTox_GSID_22557; adenine-ring; CAS-73-24-5; 66224-65-5; 71660-29-2; Leucon (TN); Adenine (8CI); Adenine (JAN/USP); Adenine [USP:JAN]; SR-05000001754; 6-Aminopurine (Adenine); 3H-PURIN-6-AMINE; 1H-Purin-6-amine (9CI); 3h-adenine; 6-amino purine; 6-amino-Purine; 1jys; 1nli; 1wei; 2pqj; 3kpv; [3H]adenine; Adenine, 1; Adenine,(S); ALBB-005925; 6-Aminopurine phospha; 7H-purin-6-ylamine; PubChem9587; Adenine phosphate salt; 9H-Purin-6-yl-amin; PubChem14133; Spectrum_001106; 2p8n; 9H-Purin-6-yl-amine; SpecPlus_000535; Adenine, >=99%; 9H-Purin-6-amine #; Spectrum2_000583; Spectrum3_000616; Spectrum4_001891; Spectrum5_000542; 6-Aminopurine; Vitamin B4; 3H-purin-6(9H)-imine; bmse000060; bmse000861; bmse000995; Epitope ID:140097; SCHEMBL8110; 6-Aminopurine; Vitamin B4; ACMC-1BC21; Oprea1_057274; US9138393, Adenine; US9144538, Adenine; BSPBio_002152; KBioGR_002447; KBioGR_002562; KBioSS_001586; KBioSS_002571; ZINC882; KSC375M3B; MLS001066342; 3H-Purin-6-amine (9CI); 7H-Purin-6-amine (9CI); 9H-Purin-6-amine (9CI); DivK1c_006631; SPECTRUM1500807; SPBio_000426; GTPL4788; 9H-Purine,6-dihydro-6-imino-; DTXSID6022557; BDBM33218; CTK1I0610; CTK1I0611; CTK2H5630; CTK2H5631; CTK8C4706; CTK8J9100; CTK8J9101; CTK8J9102; KBio1_001575; KBio2_001586; KBio2_002562; KBio2_004154; KBio2_005130; KBio2_006722; KBio2_007698; KBio3_001652; KBio3_003040; cMAP_000085; BCPP000433; BDBM181146; HMS1921I14; HMS2092K20; HMS2269I04; Pharmakon1600-01500807; BCP02865; HY-B0152; NSC14666; 6H-Purin-6-imine, 1,9-dihydro-; Tox21_111348; Tox21_302108; ANW-36312; ANW-72859; BBL007925; CA0118; CCG-38506; HTS027705; NSC757793; s1981; SBB017528; STK387542; WLN: T56 BM DN FN HNJ IZ; AKOS000118903; AKOS005171607; Tox21_111348_1; AC-2028; AM83908; BCP9000233; CS-1984; DB00173; MCULE-6556342774; NSC-757793; RTR-023809; SDCCGMLS-0066584.P001; NCGC00094856-02; NCGC00094856-03; NCGC00094856-05; NCGC00255120-01; 66224-67-7; 66224-68-8; 66224-69-9; 71660-30-5; AK-96693; AS-11841; BL008313; LS-15058; NCI60_000998; SC-09021; SMR000471871; SBI-0052324.P002; AB1004094; AB1009319; Adenine, Vetec(TM) reagent grade, >=99%; DB-013503; ST2408921; TC-161604; TR-023809; A0149; FT-0082877; FT-0620943; FT-0656198; ST50298870; T6972; 4175-EP2270010A1; 4175-EP2270015A1; 4175-EP2270505A1; 4175-EP2272517A1; 4175-EP2275404A1; 4175-EP2292088A1; 4175-EP2292593A2; 4175-EP2295441A2; 4175-EP2295503A1; 4175-EP2295550A2; 4175-EP2298783A1; 4175-EP2301536A1; 4175-EP2301538A1; 4175-EP2303884A1; 4175-EP2305250A1; 4175-EP2305808A1; 4175-EP2311455A1; 4175-EP2316452A1; 73A245; Adenine, suitable for cell culture, BioReagent; C-4677; C00147; D00034; Q15277; AB00052833-18; AB00052833-19; AB00052833_20; AB00052833_22; AB00052833_23; AB00052833_24; 6-Aminopurine hemisulfate salt; Adenine sulfate salt; Q-200595; SR-05000001754-1; SR-05000001754-2; W-106856; Adenine, BioReagent, plant cell culture tested, >=99%; Adenine, European Pharmacopoeia (EP) Reference Standard; F0001-1848; Z1250132272; 6379C0E0-C1BB-4087-96C5-1DE281B8EA4C; Adenine, United States Pharmacopeia (USP) Reference Standard; Adenine, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10; Adenine; ADE
Adenosine adenosine; 58-61-7; Adenocard; Adenoscan; Adenine riboside; beta-D-Adenosine; Nucleocardyl; Adenosin; Boniton; Sandesin; Myocol; Adenine nucleoside; Adenocor; beta-Adenosine; 9-beta-D-Ribofuranosyladenine; 9-beta-D-Ribofuranosidoadenine; Adenosin [German]; USAF CB-10; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9beta-D-Ribofuranosyladenine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Ade-Rib; Caswell No. 010B; Adenosine [USAN:BAN]; beta-D-Ribofuranoside, adenine-9; 6-Amino-9beta-D-ribofuranosyl-9H-purine; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; SR 96225; 3H-adenosine; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; NSC 7652; UNII-K72T3FS567; CCRIS 2557; Adenosine (Adenocard); CHEBI:16335; AI3-52413; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; EINECS 200-389-9; MFCD00005752; CHEMBL477; NSC 627048; SR-96225; D-Adenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; adenine-D-ribose; OIRDTQYFTABQOQ-KQYNXXCUSA-N; K72T3FS567; Adenosine, 99+%; Adenine-9-beta-D-ribofuranoside; NCGC00023673-05; Polyadenosine; Pallacor; Polyriboadenosine; DSSTox_CID_2558; DSSTox_RID_76628; DSSTox_GSID_22558; alpha-Adenosine; L-Adenosine; .beta.-D-Adenosine; CAS-58-61-7; Adenocard (TN); Adenoscan (TN); SMR000058216; MEDR-640; Adenine 9-beta-D-arabinofuranoside; Adenosine, homopolymer; Adenosine (JAN/USP); SR-05000001981; 9-.beta.-d-Ribofuranosyladenine; NSC7652; Adenogesic; Adenosine [USAN:USP:BAN]; Adenin riboside; NSC-7652; .beta.-D-Ribofuranoside, adenine-9; 9-.alpha.-D-Arabinofuranosyladenine; NSC627048; b-D-Adenosine; HSDB 7774; SUN-Y4001; N6-Methylado; 1dgm; 1odi; 2fqy; 2ydo; 3axz; 4cki; 4ckj; Adenosine,(S); adenosine-N-15N; adenosine-8-13C; adenosine-9-15N; beta-delta-Adenosine; [U-14C]adenosine; 6-Amino-9.beta.-D-ribofuranosyl-9H-purine; PubChem9306; 2gl0; 3ay0; 4pd9; Adenosine, >=99%; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; Spectrum2_001257; Spectrum3_000288; cid_191; SCHEMBL731; bmse000061; bmse000996; Epitope ID:140947; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 9-ss-D-Ribofuranosyladenine; Adenine riboside; D-Adenosine; BSPBio_001796; .beta.-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; cid_60961; KSC269K8P; MLS000069638; MLS002153227; MLS006010946; SPECTRUM1500107; Adenine-9-ss-D-ribofuranoside; REGID_for_CID_60961; SPBio_001194; adenine-9beta-D-Ribofuranoside; GTPL2844; 9beta-delta-Ribofuranosyladenine; DTXSID1022558; BDBM14487; CTK1G9587; KBio3_001296; 9-beta-delta-Ribofuranosyladenine; EA6C60C2-6AFB-4264-A2F0-541373DB950E; 9-.beta.-D-Ribofuranosidoadenine; 9-beta-delta-Ribofuranosidoadenine; adenine-9beta-delta-Ribofuranoside; Bio1_000437; Bio1_000926; Bio1_001415; HMS1920A13; HMS2091G13; HMS2235E24; Pharmakon1600-01500107; ACT02616; ALBB-032827; XYA; ZINC2169830; 9-beta-delta-Arabinofuranosyladenine; Tox21_110891; adenosine-2-13C-N,1,3-15N3; ANW-32994; CCG-38824; NSC755857; s1647; AKOS015888594; Tox21_110891_1; AC-8229; AM83931; DB00640; MCULE-7071766082; NSC-755857; RTR-020367; SDCCGMLS-0003108.P003; 9-?-D-Ribofuranosyl-9H-purin-6-amine; KS-0000010G; 9beta-D-ribofuranosyl-9H-Purin-6-amine; NCGC00023673-03; NCGC00023673-04; NCGC00023673-06; NCGC00023673-07; NCGC00178869-03; 30143-02-3; 9-? -D-Ribofuranosyl-9H-purin-6-amine; AC-27494; AS-12664; AT-11502; BR-77288; LS-15085; ST009496; Adenosine, Vetec(TM) reagent grade, 98%; SBI-0206673.P002; 9beta-delta-ribofuranosyl-9H-Purin-6-amine; AB0012292; DB-022408; ST2407911; TR-020367; 6-Amino-9beta-delta-ribofuranosyl-9H-purine; 9-.beta.-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-delta-Ribofuranosyl-9H-purin-6-amine; A0152; FT-0082881; FT-0620931; 9H-Purin-6-amine, 9-.beta.-d-ribofuranosyl-; C00212; D00045; S-3476; AB00384349-11; AB00384349_13; AB00384349_14; Adenosine, BioReagent, suitable for cell culture; Q190012; SR-05000001981-1; SR-05000001981-2; Z1741978458; 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose; Adenosine, European Pharmacopoeia (EP) Reference Standard; Formycin A, from Streptomyces kaniharaensis, >=98% (HPLC); 1-(6-amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose; Adenosine, United States Pharmacopeia (USP) Reference Standard; Adenosine, Pharmaceutical Secondary Standard; Certified Reference Material; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 158749-77-0; 177030-94-3; 244769-76-4; 41547-82-4; Adenine nucleoside
Adenosine monophosphate 5'-Adenylic acid; Adenosine monophosphate; A5MP
Adenosine-5'-triphosphate Adenosine-5'-(tetrahydrogen triphosphate); Adenosine, 5'-(tetrahydrogen triphosphate); Adenosine triphosphate
Agmatine 1-Guanidino-4-aminobutane (Sulfuric acid); Agmatine; Agmatine
Alanine L-Alanine; L-alanine; 56-41-7; alanine; (S)-Alanine; H-Ala-OH; L-alpha-alanine; (S)-2-Aminopropanoic acid; (2S)-2-Aminopropanoic acid; L-2-Aminopropionic acid; L-(+)-Alanine; L-2-Aminopropanoic acid; 2-Aminopropionic acid; alpha-Alanine; L-alpha-Aminopropionic acid; alpha-Aminopropionic acid; L-2-Aminopropionsaeure; Alaninum [Latin]; (S)-(+)-Alanine; L-S-Aminopropionic acid; (L)-Alanine; Alanine (VAN); (S)-2-Aminopropionsaeure; Poly-L-alanine; 2-Aminopropanoic acid, L-; (S)-alpha-Aminopropionsaeure; Alanine [USAN:INN]; Alanina [DCIT,Spanish]; L-a-Aminopropionic acid; L-Alanin; ALANINE, L-; Propanoic acid, 2-amino-, (S)-; HSDB 1801; UNII-OF5P57N2ZX; (S)-2-Aminopropionic acid; NSC 206315; ALA; EINECS 200-273-8; MFCD00064410; OF5P57N2ZX; CHEMBL279597; CHEBI:16977; QNAYBMKLOCPYGJ-REOHCLBHSA-N; Alanine (L-Alanine); LPG; polyalanine; L-Alanine, 99%; Alaninum; a-Alanine; Poly-DL-alanine; L-a-Alanine; 14C-L-Alanine; a-Aminopropionic acid; (2S)-2-aminopropanoate; (C14)L-Alanine; .alpha.-Alanine; (2S)-2-azaniumylpropanoate; L-.alpha.-Alanine; L-Alanine, N-coco alkyl derivs.; L-&alpha-alanine; 18875-37-1; Alanine (USP); L-Alanine (9CI); 2-Ammoniopropanoate; Propanoic acid, 2-amino-; .alpha.-Aminopropionic acid; L-Alanine, homopolymer; L-Alanine, labeled with carbon-14; L-.alpha.-Aminopropionic acid; Ritalanine; Racemic alanine; L-Alanine, 99%, specified according to the requirements of Ph.Eur.; L-aAlanine; a-Aminopropionate; L-Alanine, labeled with tritium; 3h-l-alanine; Propanoic acid, 2-amino-, (S); [3H]alanine; L-a-Aminopropionate; L-Ala; [14C]alanine; [3H]-alanine; alpha-Aminopropanoate; alpha-Aminopropionate; L-2-Aminopropanoate; L-2-Aminopropionate; L-Alanine,(S); [14C]-alanine; L-alpha-Aminopropionate; PubChem12862; Tocris-0205; 2-Ammoniopropanoic acid; ALA-OH; L-Alanine (JP17); (S)-2-Aminopropanoate; alpha-Aminopropanoic acid; L-Ala-2; (S)-2-amino-Propanoate; L-Alanine, >=99%; bmse000028; bmse000994; EC 200-273-8; L-CH3CH(NH2)COOH; GTPL720; (S)-2-amino-Propanoic acid; 130380-93-7; KSC269I4B; (2S)-2-azanylpropanoic acid; Alanine, L- (7CI,8CI); GTPL4542; GTPL4543; CTK1G9440; DTXSID20873899; L-Alanine, >=98% (TLC); L-Alanine, 99%, natural, FG; F4F207FF-8FF8-4789-99A1-147AE0A36673; HY-N0229; KS-000001XZ; STR01663; ZINC4658553; L-Alanine, >=99.0% (NT); AC-014; ANW-32509; BDBM50000099; s5631; AKOS010367904; AKOS015840030; AB02601; CS-W020002; DB00160; MCULE-7791919887; RTC-066531; L-Alanine, purum, >=98.0% (NT); NCGC00024494-01; 25191-17-7; AC-24031; BP-13281; BR-49082; LS-15737; SC-09272; L-Alanine, BioUltra, >=99.5% (NT); AB0052222; AB1002630; DB-029940; L-Alanine, SAJ special grade, >=99.0%; ST2413186; TC-066531; A0179; AM20100374; FT-0627654; FT-0657966; C00041; D00012; M-5982; 31279-EP2274983A1; 31279-EP2308858A1; 31279-EP2311816A1; 31279-EP2311817A1; 34146-EP2289892A1; 34146-EP2301939A1; 34146-EP2305687A1; 34146-EP2311850A1; 064A410; A803529; Q218642; SR-01000597687; J-015860; Q-201274; SR-01000597687-3; (S)-2-Aminopropionic acid; L-|A-Aminopropionic acid; L-Alanine, certified reference material, TraceCERT(R); Alanine, European Pharmacopoeia (EP) Reference Standard; F0001-2354; Z940713326; UNII-0O72R8RF8A component QNAYBMKLOCPYGJ-REOHCLBHSA-N; UNII-1FU7983T0U component QNAYBMKLOCPYGJ-REOHCLBHSA-N; L-Alanine, United States Pharmacopeia (USP) Reference Standard; L-Alanine, Pharmaceutical Secondary Standard; Certified Reference Material; 115967-49-2; 77160-91-9; L-Alanine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, >=98.5%; L-Alanine, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture; Alanine; Alanina [DCIT,Spanish]
Albaconazole 7-Chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4(3H)-quinazolinone; Albaconazole; UR-9825
Alclofenac ALCOFENAC; Alclofenac; W 7320
Aldosterone (11Beta)-11,21-Dihydroxy-3,20-dioxo-pregn-4-en-18-al; ALDOSTERONE; 52-39-1; Electrocortin; Aldocortin; Aldocorten; Aldocortene; (+)-Aldosterone; Elektrocortin; d-Aldosterone; Reichstein X; 18-Oxocorticosterone; Aldosteronum [INN-Latin]; Aldosterona [INN-Spanish]; [3H]aldosterone; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; Aldosterone [INN:BAN:DCF]; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; Aldosteronum; NSC 73856; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; UNII-4964P6T9RB; Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11beta)-; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; EINECS 200-139-9; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al; BRN 3224996; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; CHEBI:27584; Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11b)-; PQSUYGKTWSAVDQ-ZVIOFETBSA-N; 4964P6T9RB; Aldosterone, 98%; NSC-73856; Aldosterona; 18-Aldocorticosterone; [3H]-aldosterone; SMR000857170; 11.beta.,21-Dihydroxypregn-4-ene-3,18,20-trione; Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11.beta.)-; Aldosterone (INN); 18-ketocorticosterone; 11b,21-dihydroxy-3,20-dioxo-pregn-4-en-18-al; SCHEMBL1675; (11beta)-11,21-dihydroxy-3,20-dioxo-Pregn-4-en-18-al; 4-08-00-03491 (Beilstein Handbook Reference); MLS001333163; MLS001333164; BIDD:ER0511; CHEMBL273453; GTPL2872; GTPL3452; DTXSID7022419; Aldosterone, >=95% (HPLC); BDBM19214; CTK8A1117; HMS2233D14; NSC73856; ZINC3833824; 1604AH; LMST02030026; MFCD00051136; AKOS024462706; DB04630; EBD2202795; NCGC00164236-01; AS-69489; SC-13315; HY-113313; LS-118602; TR-018591; CS-0059576; ST24045930; C01780; D10528; Q184564; SR-01000838883; SR-01000838883-2; Pregn-4-en-18-al,21-dihydroxy-3,20-dioxo-, (11.beta.)-; Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11-beta)-; (11alpha,14beta,17alpha)-11,21-dihydroxy-3,20-dioxopregn-4-en-18-al; (1S,2R,10S,11S,14S,15R,17S)-17-hydroxy-14-(2-hydroxyacetyl)-2-methyl-5-oxotetracyclo[8.7.0.0; {2,7}.0; {11,15}]heptadec-6-ene-15-carbaldehyde; Aldosterone solution, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; Aldosteronum; delta-Aldosterone; 11,21-Dihydroxy-3,20-dioxopregn-4-en-18-al; 11b,21-dihydroxy-3,20-dioxo-pregn-4-en-18-al; (11beta)-11,21-dihydroxy-3,20-dioxo-Pregn-4-en-18-al; SCHEMBL14373307; 11beta,21-Dihydroxy-3,20-dioxo-pregn-4-en-18-al; (11b)-11,21-dihydroxy-3,20-dioxo-pregn-4-en-18-al; 11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; Aldosterone; 4-08-00-03491 (Beilstein Handbook Reference)
Alfentanil N-[1-[2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-N-phenylpropanamide; Alfentanil; 5-26-13-00110 (Beilstein Handbook Reference)
Alfuzosin N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide; alfuzosin; 81403-80-7; AlfuzosiAlfuzosine; Alfuzosinum; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosina [Spanish]; Alfuzosin [INN:BAN]; ALFLUZOCIN; SL 77499; HSDB 7290; SL 77-499; CHEMBL709; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; CHEBI:51141; WNMJYKCGWZFFKR-UHFFFAOYSA-N; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide; Alfusosine; C19H27N5O4; alphuzosine; N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide; Alfuzosin (INN); 2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-; SMR000466340; Xatral (TN); SL-77499-10; Alfuzosin/; N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl); SR-01000759345; n-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide; ALFLUZOSIN; Prestwick0_000322; Prestwick1_000322; Prestwick2_000322; Prestwick3_000322; Spectrum2_000505; Spectrum3_001063; Spectrum4_001208; Spectrum5_000817; SCHEMBL34477; BSPBio_000323; BSPBio_002646; KBioGR_001616; MLS000759449; MLS001424027; MLS006011887; SPECTRUM1505263; SPBio_000429; SPBio_002244; BPBio1_000357; GTPL7109; DTXSID6048549; KBio3_001866; HMS1922P11; HMS2051I10; HMS2093O06; HMS2235O22; HMS3369K03; HMS3393I10; HMS3749I05; Pharmakon1600-01505263; ACT03219; HY-B0192; ABP000595; BDBM50033110; BG0022; CCG-39585; NSC760065; s5766; STK643675; AKOS005574697; API0001406; CCG-100859; CS-2086; DB00346; MCULE-9094645643; NC00109; NSC-760065; SDCCGSBI-0206735.P002; VA10203; NCGC00095152-01; NCGC00095152-02; NCGC00095152-03; NCGC00095152-04; NCGC00095152-05; NCGC00095152-07; CC-23834; CPD000466340; K449; LS-70106; SAM001246638; SC-17006; SBI-0206735.P001; AB0014226; DB-056523; AB00514667; FT-0630891; D07124; AB00514667-07; AB00514667-09; AB00514667-10; AB00514667_11; AB00514667_12; (methyl)amino)propyl)tetrahydrofuran-2-carboxamide; 403A807; A840122; C-21524; L001317; Q2736873; SR-01000759345-4; BRD-A09056319-001-02-2; BRD-A09056319-001-05-5; BRD-A09056319-003-03-6; N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)-methylamino]propyl]-2-oxolanecarboxamide; N-[3-[(4-azanyl-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]oxolane-2-carboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide; (+/-)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide; 2-Furancarboxamide,N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-; N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide; N-{3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)(methyl)amino]propyl}tetrahydro-2-furancarboxamide; N-{3-[(4-imino-6,7-dimethoxy-3,4-dihydroquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboximidic acid; Alfuzosin; Alfuzosina [Spanish]
Allicin 2-Propene-1-sulfinothioic acid S-2-propenyl ester; Allicin; 4-04-00-00007 (Beilstein Handbook Reference)
Almotriptan N,N-Dimethyl-5-[(1-pyrrolidinylsulfonyl)methyl]-1H-indole-3-ethanamine; Almotriptan; UNII-1O4XL5SN61
Alprenolol 1-[(1-Methylethyl)amino]-3-[2-(2-propen-1-yl)phenoxy]-2-propanol; Alprenolol; Alfeprol [Russian]
Alprostadil (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid; Alprostadil; U 10136
Altretamine N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-triazine-2,4,6-triamine; altretamine; 645-05-6; HEXAMETHYLMELAMINE; Hexalen; Hexastat; Hemel; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; Melamine, hexamethyl-; Altretaminum; AltretamiAltretaminum [INN-Latin]; ENT 50852; NC 195; 2,4,6-Tris(dimethylamino)-s-triazine; NCI-C50259; HMM; Altretamina [INN-Spanish]; N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine; Altretamine (Hexalen); NSC 13875; HTM; HXM; s-Triazine, 2,4,6-tris(dimethylamino)-; UNII-Q8BIH59O7H; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl-; CCRIS 5492; MLS000069621; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; C9H18N6; NSC13875; EINECS 211-428-4; NSC-13875; BRN 0195058; Q8BIH59O7H; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine; SMR000058181; AI3-50852; CHEBI:24564; UUVWYPNAQBNQJQ-UHFFFAOYSA-N; NCGC00015100-02; DSSTox_CID_2579; DSSTox_RID_76641; DSSTox_GSID_22579; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N',N'-hexamethyl-; CAS-645-05-6; Hexalen (TN); Altretamine [USAN:INN:BAN]; SR-01000000117; Hexalen [Antineoplastic]; Altretamine (USP/INN); Altretamine/; HSDB 7559; Altretamine, solid; Altretamine [USAN:USP:INN:BAN]; KB-913; Spectrum_001308; Opera_ID_1095; Prestwick0_000946; Prestwick1_000946; Prestwick2_000946; Prestwick3_000946; Spectrum2_000907; Spectrum3_000951; Spectrum4_001064; Spectrum5_001092; Lopac-A-8723; ChemDiv2_005185; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; A 8723; Cambridge id 5148727; cid_2123; SCHEMBL4206; CHEMBL1455; Lopac0_000083; BSPBio_000912; KBioGR_001388; KBioSS_001788; ZINC905; MLS001076123; DivK1c_000772; SPECTRUM1503065; SPBio_000754; SPBio_003071; BPBio1_001004; GTPL7112; DTXSID4022579; BDBM37631; CTK8F7682; HMS502G14; KBio1_000772; KBio2_001788; KBio2_004356; KBio2_006924; KBio3_002042; NINDS_000772; BCPP000413; HMS1383L15; HMS1570N14; HMS1922C05; HMS2090G17; HMS2092H16; HMS2097N14; HMS2234F09; HMS3259I20; HMS3260A08; HMS3372H17; HMS3654H11; HMS3714N14; Pharmakon1600-01503065; BCP27675; CCG-2238; HY-B0181; KS-00001F6N; 2,6-Tris(dimethylamino)-s-triazine; Tox21_110085; Tox21_202784; Tox21_500083; ABP000596; NSC758231; s1278; STK749184; s-Triazine,4,6-tris(dimethylamino)-; AKOS001729401; Tox21_110085_1; BCP9000278; CS-2061; DB00488; KS-5247; LP00083; LS-1549; MCULE-1605383293; NC00595; NSC-758231; SDCCGSBI-0050071.P004; VA10242; IDI1_000772; IDI1_003900; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; NCGC00015100-01; NCGC00015100-03; NCGC00015100-04; NCGC00015100-05; NCGC00015100-06; NCGC00015100-07; NCGC00015100-08; NCGC00015100-09; NCGC00015100-10; NCGC00015100-11; NCGC00015100-12; NCGC00015100-14; NCGC00015100-15; NCGC00021216-03; NCGC00021216-04; NCGC00021216-05; NCGC00021216-06; NCGC00021216-07; NCGC00260330-01; NCGC00260768-01; AC-12006; AK431828; CAS-654-05-6; CPD000058181; NCI60_000871; SAM002564241; SC-26614; ST086739; 2,6-Tris(dimethylamino)-1,3,5-triazine; SBI-0050071.P003; AB0007992; AB2000024; DB-054676; AB00052308; EU-0100083; FT-0083576; FT-0651499; SW102053-5; D02841; M-2093; 49712-EP2295426A1; 49712-EP2295427A1; 49712-EP2308833A2; 49712-EP2311825A1; AB00052308-16; AB00052308-17; AB00052308-18; AB00052308_19; AB00052308_20; 645A056; A834788; Q415242; WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1; 2,4,6-Tris(dimethylamino)-1,3,5-triazine, 96%; J-523408; SR-01000000117-2; SR-01000000117-4; SR-01000000117-6; BRD-K67043667-001-04-1; BRD-K67043667-001-15-7; Z57931197; 645-05-6,2975-00-0(HCl); Altretamine [2,4,6-Tris(dimethylamino)-1,3,5-triazine]; [4,6-bis(dimethylamino)(1,3,5-triazin-2-yl)]dimethylamine; N2,N2,N4,N4,N6,N6-Hexamethyl-1,3,5-trazne-2,4,6-tramne; 1,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl-; Altretamine, United States Pharmacopeia (USP) Reference Standard; N-[4,6-bis(dimethylamino)-1,3,5-triazin-2-yl]-N,N-dimethylamine; 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'', N''-hexamethyl-; InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H; Altretamine; 4-26-00-01256 (Beilstein Handbook Reference)
Aluminium hydroxide (Al(OH)3) Aluminium hydroxide; C.I. 77002; Aluminium hydroxide
Amantadine Tricyclo[3.3.1.13,7]decan-1-amine; amantadine; 1-Adamantanamine; 768-94-5; adamantan-1-amine; 1-Adamantylamine; 1-Aminoadamantane; Adamantanamine; Adamantylamine; Aminoadamantane; Symmetrel; Amantidine; Pk-merz; Adamantamine; Symadine; 1-Adamantamine; AmantadiAmantadinum; Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Amantadina [INN-Spanish]; adamantan-1-ylamine; Gocovri; TCMDC-125869; 1-adamantaneamine; UNII-BF4C9Z1J53; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; NSC 341865; Tricyclo(3.3.1.13,7)decan-1-amine; HSDB 3202; tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; EINECS 212-201-2; CHEMBL660; BRN 2204333; adamantanylamine; (3s,5s,7s)-Tricyclo[3.3.1.1~3,7~]decan-1-Amine; BF4C9Z1J53; CHEBI:2618; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; DKNWSYNQZKUICI-UHFFFAOYSA-N; MFCD00074732; NSC341865; NSC-341865; NCGC00015036-03; Tricyclo[3.3.1.13,7]decan-1-amine; AK-77141; Tricyclo[3.3.1.13,7]decane-1-amine; Wiregyt; Amantadine Base; 1-Adamantanamine, 96%; DSSTox_CID_2117; DSSTox_RID_76493; DSSTox_GSID_22117; J-650234; Amant; Amantadine (INN); CAS-768-94-5; NSC83653; 1-Adamantanamine (8CI); ADAMANTANE,1-AMINO; adamantaneamine; adamantyl amine; AmantadineHCl; 1-admantaneamine; 1-Amantadine; 1-adamantanylamine; BIA4304; 1-adamantyl amine; Adamant-1-ylamine; 1-amino-adamantane; adamantane-1-amine; PubChem8733; OR14310; Mantadine (Salt/Mix); Symmetrel (Salt/Mix); PubChem13903; Spectrum_000030; Tricyclo[3.3.1.1^3,7]decan-1-amine; Prestwick0_000407; Prestwick1_000407; Prestwick2_000407; Prestwick3_000407; Spectrum2_000081; Spectrum3_000291; Spectrum4_000134; Spectrum5_000772; tricyclo[3.3.1.1(3,7)]decan-1-ylamine; tricyclo[3.3.1.1(3,7)]decane-1-amine; 1-Adamantylamine, 97%; Lopac-A-1260; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; EC 212-201-2; SCHEMBL4098; NCIOpen2_001059; Lopac0_000004; Oprea1_248648; BSPBio_000334; BSPBio_001570; BSPBio_001822; KBioGR_000548; KBioSS_000390; KSC492O9F; BIDD:GT0757; CHEMBL19601; DivK1c_000815; Exp-105-1 (Salt/Mix); SPBio_000002; SPBio_002273; BPBio1_000368; GTPL4128; SCHEMBL2619248; DTXSID8022117; SCHEMBL15672299; SCHEMBL20409394; SCHEMBL21309814; SCHEMBL21310017; CTK3J2792; KBio1_000815; KBio2_000390; KBio2_002958; KBio2_005526; KBio3_001322; NINDS_000815; ZX-AFC001530; (3R,5S,7s)-Adamantan-1-amine; 1-Adamantamine(1-Aminoadamantane); HMS1791O12; HMS1989O12; HMS3604O07; ZINC968256; ACT02873; ALBB-013871; BCP09869; STR04703; ZX-AN012620; ZX-AT007596; Tox21_110068; ANW-43040; BBL004977; BDBM50033369; HTS001826; s5499; SBB071506; STK298781; AKOS000113994; AKOS000119324; AKOS007930692; AKOS015935124; Tox21_110068_1; CA-1981; CCG-204100; CS-W008656; DB00915; FCH2250665; MCULE-9686682307; SDCCGSBI-0049993.P005; TRA0073510; IDI1_000815; KS-00000X47; NCGC00015036-01; NCGC00015036-02; NCGC00015036-04; NCGC00015036-05; NCGC00015036-06; NCGC00015036-07; NCGC00015036-08; NCGC00015036-09; NCGC00015036-11; NCGC00015036-13; NCGC00162039-01; NCGC00162039-02; NCGC00162039-03; NCGC00162039-04; NCGC00179597-01; AC-25879; ADS-5102, EXP 105-1; AS-14215; BBV-38789958; BP-13040; CC-03900; K333; SC-06708; ST097860; SBI-0049993.P004; AB0014168; AX8000305; LS-157049; RT-001031; ST2412621; WLN: L66 B6 A B- C 1B ITJ BZ; AB00514655; FT-0607338; EN300-33893; C06818; D07441; M-4039; AB00053414-14; AB00053414-16; AB00053414_17; AB00053414_18; AB01275427-01; 768A945; A838887; AE-641/01634060; C-02982; L000868; Q409761; W-104338; BRD-K70330367-003-01-2; BRD-K70330367-003-03-8; Q27453436; F0001-1962; InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H; Amantadine; Adamantanamine
Amidate (R)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; Etomidate; R 16659
Amiloride 3,5-Diamino-N-(aminoiminomethyl)-6-chloro-2-pyrazinecarboxamide; Amiloride; Amilorida [INN-Spanish]
Aminoacridine 9-Aminoacridine; 9-AMINOACRIDINE; Acridin-9-amine; Aminacrine; 90-45-9; 9-Acridinamine; Aminoacridine; Aminacrin; Izoacridina; Monacrin; 10-Amino-5-azaanthracene; 9-Acridinylamine; Aminoacridina; Aminoacridinum; 9-Aminoakridin; Acridine, 9-amino-; 9-Aminoacridin; 9(10H)-Acridinimine; 9-Aminoakridin [Czech]; Aminoacridine [INN:BAN]; 9AA; UNII-78OY3Z0P7Z; NSC 13000; CCRIS 748; 9-AA; Acridin-9-ylamine; NSC 7571; EINECS 201-995-6; BRN 0141171; AI3-51012; 78OY3Z0P7Z; CHEBI:74789; XJGFWWJLMVZSIG-UHFFFAOYSA-N; acridine-9-ylamine; AK109135; Aminopt; Mykocert; 110166-26-2; CS-003/03975023; WLN: T C666 BNJ IZ; MLS000780068; NSC7571; 8AD; SMR000420251; iminoacridan; Aminoacrid; 9-Amino-acridin; 4bds; 9-Amino-acridine; F2179-0009; acridin-9-yl-amine; Quench (Salt/Mix); ACMC-20mczt; Mycosert (Salt/Mix); Spectrum_001108; SpecPlus_000861; 9-Acridinamine (9CI); 65944-23-2; Spectrum2_001112; Spectrum3_000617; Spectrum4_000580; Spectrum5_001498; Acramine Yellow (Salt/Mix); SCHEMBL14999; BSPBio_002154; KBioGR_001020; KBioSS_001588; BIDD:GT0816; CHEMBL43184; DivK1c_006957; SPECTRUM1500810; SPBio_001244; DTXSID2024456; BDBM72700; cid_2723598; CTK0G2217; KBio1_001901; KBio2_001588; KBio2_004156; KBio2_006724; KBio3_001654; KS-00000GTZ; XJGFWWJLMVZSIG-UHFFFAOYSA-; HMS1921I16; HMS2092K22; HMS3715H04; Pharmakon1600-01500810; 9-acridinamine; hydrate; hydrochloride; ALBB-020726; BCP25849; HY-B1422; NSC13000; NSC28747; ZX-AN019316; ANW-75188; BBL011755; CCG-39037; MFCD00037839; NSC-13000; NSC-28747; NSC757794; s4303; SBB003606; STK387428; ZINC19014768; AKOS000120447; acridin-9-ylamine; hydrate; hydrochloride; CS-4915; DB11561; LS-1913; MCULE-4734217474; NSC-757794; NCGC00094857-01; NCGC00094857-02; NCGC00094857-03; 7AD; AS-17405; CC-23490; ST093685; SY039786; U978; SBI-0051612.P002; AX8014518; DB-026983; TC-163933; A2905; FT-0621612; ST24045903; SW219793-1; EN300-17076; M-2337; AB00052180_09; AB00052180_10; C-08694; Q513937; SR-01000760844; CU-01000012501-2; SR-01000760844-2; BRD-K00535541-001-02-2; BRD-K00535541-311-04-1; 9-Aminoacridine, matrix substance for MALDI-MS, >=99.5% (HPLC); 9-AMINOACRIDINE (SEE ALSO 9-AMINOACRIDINE HCL AND 9-AMINOACRIDINE HCL-H2O); InChI=1/C13H10N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8H,(H2,14,15); Aminacrine; 9AA
Aminocaproic acid 6-Aminohexanoic acid; epsilon-Aminocaproic acid; Epsilon S
Aminocoumarins Novobiocin
Aminocyclitols Spectinomycin
Aminoglutethimide 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; aminoglutethimide; 125-84-8; dl-Aminoglutethimide; Cytadren; Orimeten; p-Aminoglutethimide; Elipten; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; Aminoglutetimida; 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-; Aminoglutethimidum; 2-(p-Aminophenyl)-2-ethylglutarimide; Ba-16038; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine; (+/-)-p-AMINOGLUTETHIMIDE; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Glutethimide, para-amino; Ba 16038; C 16038-BA; AG-1; CCRIS 7562; Glutarimide, 2-(p-aminophenyl)-2-ethyl-; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; EINECS 204-756-4; CHEMBL488; BRN 0210656; CHEBI:2654; alpha-(p-Aminophenyl)-alpha-ethylglutarimide; ROBVIMPUHSLWNV-UHFFFAOYSA-N; 3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione; NSC-330915; DSSTox_CID_2589; DSSTox_RID_76647; .alpha.-(p-Aminophenyl)-.alpha.-ethylglutarimide; DSSTox_GSID_22589; (RS)-2-(4-Amino-phenyl)-2-ethyl-glutarimide; (RS)-3-(4-Amino-phenyl)-3-ethyl-2,6-dioxo-piperidine; Aminoglutetimide; Cytadren (TN); SMR000326785; Aminoglutethimide [INN:BAN]; aminoglutethimide (AG); SR-01000075596; Aminoglutethimide (USP/INN); HSDB 7494; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; Aminoglutethimide [USP:INN:BAN]; NCGC00016379-01; CAS-125-84-8; Prestwick_243; Spectrum_000040; (y)-p-Aminoglutethimide; Aminoglutethimide AG, 4; (?)-p-Aminoglutethimide; Prestwick0_000244; Prestwick1_000244; Prestwick2_000244; Prestwick3_000244; Spectrum2_000093; Spectrum3_000296; Spectrum4_000144; Spectrum5_000802; A 9657; SCHEMBL4306; Aminoglutethimide (Cytadren); Lopac0_000124; BSPBio_000028; BSPBio_001832; KBioGR_000588; KBioSS_000400; (A+/-)-p-Aminoglutethimide; MLS000859924; MLS001213216; DivK1c_000884; SPECTRUM1500115; SPBio_000046; SPBio_002247; BDBM9460; BPBio1_000032; GTPL7054; DTXSID8022589; CTK6D0224; HMS502M06; KBio1_000884; KBio2_000400; KBio2_002968; KBio2_005536; KBio3_001332; NINDS_000884; HMS1568B10; HMS1920C09; HMS2090I05; HMS2091I09; HMS2095B10; HMS2231M19; HMS3259H10; HMS3260I10; HMS3372M07; HMS3655O17; HMS3712B10; Pharmakon1600-01500115; BCP28501; EBD40055; HY-B0237; 2, 3-(4-aminophenyl)-3-ethyl-; Tox21_110406; Tox21_303497; Tox21_500124; BBL010961; CCG-38911; MFCD00010122; NSC330915; NSC755868; SBB000711; STK802074; AKOS004120070; AKOS022060651; Tox21_110406_1; AT-2947; CS-2205; DB00357; LP00124; MCULE-9118268281; NC00714; NSC-755868; SDCCGSBI-0050112.P005; IDI1_000884; SMP1_000017; NCGC00015110-02; NCGC00015110-03; NCGC00015110-04; NCGC00015110-05; NCGC00015110-06; NCGC00015110-07; NCGC00015110-09; NCGC00015110-12; NCGC00093615-01; NCGC00093615-02; NCGC00093615-03; NCGC00093615-04; NCGC00093615-05; NCGC00257263-01; NCGC00260809-01; AC-12456; AS-13282; CPD000326785; H801; LS-72014; NCI60_002900; SAM002589964; SC-12125; SBI-0050112.P004; AB0013271; AB2000209; DB-021640; DB-072002; DB-072275; AB00051935; EU-0100124; FT-0622284; S1672; SW196550-3; ( inverted question mark)-p-Aminoglutethimide; EN300-53368; VU0243029-3; C07617; D00574; K-1913; AB00051935-09; AB00051935-11; AB00051935_12; AB00051935_13; 125A848; A805433; Q241150; 3-(4-aminophenyl)-3-ethylazaperhydroine-2,6-dione; SR-01000075596-1; SR-01000075596-4; SR-01000075596-6; W-108399; BRD-A25234499-001-05-0; BRD-A25234499-001-09-2; Z1259341083; Aminoglutethimide, European Pharmacopoeia (EP) Reference Standard; Aminoglutethimide, United States Pharmacopeia (USP) Reference Standard; Aminoglutethimide; 5-22-13-00297 (Beilstein Handbook Reference)
Aminoglycosides Amikacin; Apramycin; Arbekacin; Astromicin; Bekanamycin; Dibekacin; Dihydrostreptomycin; Fremycetin; Gentamicin; Isepamicin; Kanamycin; Neomycin; Netilmicin; Paromomycin; Plazomicin; Ribostamycin; Streptomycin; Tobramycin
Aminohippuric acid N-(4-Aminobenzoyl)glycine; 4-Aminohippuric acid; aminohippuric acid; 61-78-9; P-AMINOHIPPURIC ACID; Glycine, N-(4-aminobenzoyl)-; Paha; N-(4-Aminobenzoyl)glycine; para-Aminohippuric acid; Nefrotest; 2-(4-aminobenzamido)acetic acid; N-(p-Aminobenzoyl)glycine; p-Aminohippurate; Aminohippurate; PAH (amino acid); 4-Amino hippuric acid; N-(para-aminobenzoyl)glycine; Hippuric acid, p-amino-; N-(p-Aminobenzoyl)aminoacetic acid; para-Aminohippurate; paraaminohippuric acid; PAH; 2-[(4-aminobenzoyl)amino]acetic acid; UNII-Y79XT83BJ9; NSC 13064; 2-[(4-aminophenyl)formamido]acetic acid; HSDB 2139; 4-Aminobenzoyl Glycine; EINECS 200-518-9; Aminohippuric acid [USP]; AI3-52275; Y79XT83BJ9; CHEBI:104011; N-[(4-aminophenyl)carbonyl]glycine; NSC-13064; 94-16-6; 4-Aminohippurate; CAS-61-78-9; NCGC00016279-01; Aminohippuric acid (USP); DSSTox_CID_2590; DSSTox_RID_76648; DSSTox_GSID_22590; 4-Aminohippuric acid, 99%; N-(p-Aminobenzoyl)aminoacetate; 2-[(4-aminophenyl)carbonylamino]acetic acid; SR-05000002048; Aminohippuric acid [USAN]; p-amino-hippuricaci; MFCD00007890; Spectrum_001310; (p-Aminobenzoyl)glycine; (4-aminobenzoyl)glycine; Prestwick0_000895; Prestwick1_000895; Prestwick2_000895; Prestwick3_000895; Spectrum2_001515; Spectrum3_000952; Spectrum4_001065; Spectrum5_001100; ACMC-1AY8I; CHEMBL463; Oprea1_490712; BSPBio_000710; KBioGR_001390; KBioSS_001790; MLS002154055; DivK1c_000694; SCHEMBL196513; SPECTRUM1503069; SPBio_001589; SPBio_002919; N-(4-Aminobenzoyl-d4)glycine; BPBio1_000782; GTPL4810; p-Aminohippuric acid, >=99%; DTXSID7022590; (4-Aminobenzoylamino)acetic acid; CTK3I9687; HMS502C16; KBio1_000694; KBio2_001790; KBio2_004358; KBio2_006926; KBio3_002044; KS-00000YBH; Hippuric acid, p-amino- (8CI); NSC7550; HSMNQINEKMPTIC-UHFFFAOYSA-N; NINDS_000694; HMS1570D12; HMS1922C07; HMS2092H18; HMS2097D12; HMS2233A21; HMS3373E19; HMS3651L04; HMS3714D12; Pharmakon1600-01503069; ZINC119344; ALBB-025851; BCP04299; HY-B1306; NSC-7550; NSC13064; 4-AMINOHIPPURIC ACID BIOTECH; Tox21_110345; ANW-33944; BBL027666; CCG-39181; NSC758232; s2883; SBB000329; STK801822; [(4-Aminobenzoyl)amino]acetic acid #; AKOS000120722; Tox21_110345_1; CS-4816; DB00345; MCULE-9532170257; NSC-758232; RTR-021250; VZ28181; IDI1_000694; p-Aminohippuric acid, >=98.0% (T); NCGC00016279-02; NCGC00016279-03; NCGC00016279-05; NCGC00094993-01; NCGC00094993-02; AC-29237; SMR001233372; SBI-0051760.P002; DB-053989; LS-168886; ST2416094; TR-021250; A0313; AB00052309; FT-0617576; FT-0622289; R1187; ST45029013; SW197249-3; X6859; 7E-944; A16384; D06890; AB00052309_08; Q291271; SR-05000002048-1; SR-05000002048-3; W-203306; Z1270312078; Aminohippuric acid, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13; p-Aminohippuric acid; AI3-52275